Extreme hyperuricemia is a risk factor for infection-related deaths in incident dialysis patients: a multicenter prospective cohort study

Ren Fail. 2020 Nov;42(1):646-655. doi: 10.1080/0886022X.2020.1788582.

Abstract

Introduction: There are few studies on the association between serum uric acid (UA) level and mortality in incident dialysis patients. We aimed to clarify whether the serum UA level at dialysis initiation is associated with mortality during maintenance dialysis.

Methods: We enrolled 1486 incident dialysis patients who participated in a previous multicenter prospective cohort study in Japan. We classified the patients into the following five groups according to their serum UA levels at dialysis initiation: G1 with a serum UA level <6 mg/dL; G2, 6.0-8.0 mg/dL; G3, 8.0-10.0 mg/dL; G4, 10.0-12.0 mg/dL; and G5, ≥12.0 mg/dL. We created three models (Model 1: adjusted for age and sex, Model 2: adjusted for Model 1 + 12 variables, and Model 3: stepwise regression adjusted for Model 2 + 13 variables) and performed a multivariate Cox proportional hazard regression analysis to examine the association between the serum UA level and outcomes, including infection-related mortality.

Results: Hazard ratios (HRs) were calculated relative to the G2, because the all-cause mortality rate was the lowest in G2. For Models 1 and 2, the all-cause mortality rate was significantly higher in G5 than in G2 (HR: 1.63, 95% confidence interval [CI]: 1.14-2.33 and HR: 1.78, 95% CI: 1.19-2.68, respectively). For Models 1, 2, and 3, the infection-related mortality rate was significantly higher in G5 than in G2 (HR: 2.75, 95% CI: 1.37-5.54, HR: 3.09, 95% CI: 1.45-6.59, HR: 3.37, and 95% CI: 1.24-9.15, respectively).

Conclusions: Extreme hyperuricemia (serum UA level ≥12.0 mg/dL) at dialysis initiation is a risk factor for infection-related deaths.

Keywords: Hyperuricemia; cohort; dialysis; dialysis initiation; infection; mortality.

Publication types

  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Hyperuricemia / blood
  • Hyperuricemia / complications*
  • Japan / epidemiology
  • Kidney Failure, Chronic / blood
  • Kidney Failure, Chronic / mortality*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Proportional Hazards Models
  • Prospective Studies
  • Renal Dialysis / mortality*
  • Risk Factors
  • Uric Acid / blood*

Substances

  • Uric Acid

Grants and funding

YY received research support grants from K.K. Kyowa Kirin Co., Ltd., Japan tobacco Inc., Astellas Pharma Inc., Baxter Ltd., Chugai Pharmaceutical Co., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sanofi Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., and Torii Pharmaceutical Co., Ltd. NT received research a support grant from GlaxoSmithKline.